Based on Phase 2 clinical trial data published in The New England Journal of Medicine (Jastreboff et al., 2023), retatrutide shares a side effect profile broadly consistent with other GLP-1-based therapies, though the triple receptor mechanism may introduce additional considerations
It comprises flavonoids, glycosides, and alkaloids
Further challenges stem from a lack of treatment standardization
Smith, MD, also at St Johns Institute of Dermatology, Kings College London, and senior author adds, As rates of obesity continue to rise globally, understanding how different patterns of body fat influence chronic inflammatory conditions such as psoriasis is important
Many people also report improved eating control and better metabolic health when treatment is medically supervised
PMCID: PMC6435948.